The Claim
The DiSMS and LyMedivh™ AXL plasma p-tau217 assays achieve 94.4% sensitivity and 100% specificity in distinguishing Alzheimer’s dementia from cognitively unimpaired individuals, matching the performance of the reference ALZpath Simoa assay, indicating they are viable alternatives for clinical diagnosis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Two new blood tests for p-tau217 detect Alzheimer’s dementia with 94.4% accuracy in identifying affected individuals and 100% accuracy in identifying those without dementia, performing identically to the established ALZpath Simoa assay.
See the scientific wording
The DiSMS and LyMedivh™ AXL plasma p-tau217 assays achieve 94.4% sensitivity and 100% specificity in distinguishing Alzheimer’s dementia from cognitively unimpaired individuals, matching the performance of the reference ALZpath Simoa assay, indicating they are viable alternatives for clinical diagnosis.
In Alzheimer’s disease, abnormal tau proteins clump inside brain cells and form tangles; as these tangles grow, fragments of the modified tau protein leak into the fluid around brain cells and enter the bloodstream. Blood tests can detect these fragments with extreme accuracy, distinguishing people with the disease from those without it.
What the research says
1 studyTwo new blood tests for Alzheimer’s caught 94 out of 100 people with the disease and never wrongly said someone had it when they didn’t — just like the best test we already have.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.